Log in to save to my catalogue

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Ca...

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Ca...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04390217v1

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

About this item

Full title

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Publisher

England: Elsevier Limited

Journal title

The Lancet (British edition), 2023-12, Vol.402 (10419), p.2295-2306

Language

English

Formats

Publication information

Publisher

England: Elsevier Limited

More information

Scope and Contents

Contents

Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum-pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum-pemetrexed would improve overall survival in patients with pleural mesothelioma.
We did this open-label, international, randomised phase 3 trial at 51...

Alternative Titles

Full title

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04390217v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04390217v1

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(23)01613-6

How to access this item